2024
240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey
SHERR J, HAGAN K, BHAK R, PETER M, NGUYEN H, WANG C, PAKALAPATI T, SHERWOOD J, GUPTA T, GAGLIA J, CORNELIUS E, CHAPMAN K, WOLF W, PETTUS J. 240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey. Diabetes 2024, 73 DOI: 10.2337/db24-240-or.Peer-Reviewed Original ResearchFollow-up surveySevere hypoglycemic eventsImpaired awareness of hypoglycemiaOnline surveyT1D Exchange RegistryProportion of respondentsT1D careFollow-upEligible individualsHbA1c < 7%Diabetes technologyLongitudinal trendsCGM useHbA1c targetLongitudinal assessmentInsulin delivery methodsHbA1cAwareness of hypoglycemiaSurveyParticipantsImpaired awarenessAdultsT1DRespondentsHypoglycemic eventsExploring Factors That Influence Postexercise Glycemia in Youth With Type 1 Diabetes in the Real World: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study.
Sherr J, Bergford S, Gal R, Clements M, Patton S, Calhoun P, Beaulieu L, Riddell M. Exploring Factors That Influence Postexercise Glycemia in Youth With Type 1 Diabetes in the Real World: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study. Diabetes Care 2024, 47: 849-857. PMID: 38412033, DOI: 10.2337/dc23-2212.Peer-Reviewed Original ResearchParticipants self-reported physical activitySelf-reported physical activityPostexercise recovery periodEvent-level factorsExercise sessionsPhysical activitySedentary dayExercise studiesSupport exerciseExerciseDelivery modalitiesSD ageType 1 diabetesHemoglobin A1cPostexercisePump useShorter disease durationDecision support toolGlucose dataRecovery periodHbA1cDisease durationHypoglycemia riskInsulin delivery modalityHypoglycemia ratesGlycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System
DeSalvo D, Bode B, Forlenza G, Laffel L, Buckingham B, Criego A, Schoelwer M, MacLeish S, Sherr J, Hansen D, Ly T. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System. Diabetes Technology & Therapeutics 2024, 26: 383-393. PMID: 38277156, DOI: 10.1089/dia.2023.0506.Peer-Reviewed Original ResearchType 1 diabetesExtension phaseEpisodes of diabetic ketoacidosisEpisodes of severe hypoglycemiaLong-term safetyLong-term useStandard therapyDiabetic ketoacidosisAutomated insulin deliverySevere hypoglycemiaYoung childrenConclusion:</i></b>Continuous glucose monitoring metricsExtension studyMethods:</i></b>MonthsGlycemic outcomesTarget rangeTrialsOmnipodHbA1cInsulin deliveryDelivery systemInsulin delivery systemsEpisodesReal-World Evidence of Automated Insulin Delivery System Use
Considine E, Sherr J. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics 2024, 26: 53-65. PMID: 38377315, PMCID: PMC10890954, DOI: 10.1089/dia.2023.0442.Peer-Reviewed Original ResearchConceptsGlucose management indicatorAid useRetrospective real-world studyMode of insulin deliveryGlycemic benefitsFollow-up periodTrial findingsFood and Drug AdministrationStandard of careReal-world studyInsulin deliveryType 1 diabetesNonpregnant individualsPivotal trialsRetrospective analysisPrimary outcomeHemoglobin A1cConclusion:</i></b>Drug AdministrationInclusion criteriaHbA1cGlycemic outcomesSystematic reviewResults:</i></b>Target range
2023
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes
Criego A, Carlson A, Brown S, Forlenza G, Bode B, Levy C, Hansen D, Hirsch I, Bergenstal R, Sherr J, Mehta S, Laffel L, Shah V, Bhargava A, Weinstock R, MacLeish S, DeSalvo D, Jones T, Aleppo G, Buckingham B, Ly T, Group F. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 26: 11-23. PMID: 37850941, PMCID: PMC10794844, DOI: 10.1089/dia.2023.0364.Peer-Reviewed Original ResearchConceptsAdolescents/adultsPivotal trialsInsulin delivery systemsSingle-arm multicenter trialYears of useClinical trial registrationType 1 diabetesLong-term safetyMonths of useLong-term useDiabetic ketoacidosisMulticenter trialSevere hypoglycemiaTRIAL REGISTRATIONGlycemic outcomesType 1Delivery systemExtension phaseMonthsTrialsTarget rangeAdultsHbA1cChildrenEpisodes
2020
1580-P: Hemoglobin A1c (HbA1c) Trajectories of Youth with Type 1 Diabetes (T1D) over 10 Years Postdiagnosis from Three Continents
SHERR J, SCHWANDT A, PHELAN H, CLEMENTS M, HOLL R, BENITEZ-AGUIRRE P, MILLER K, WOELFLE J, DOVER T, MAAHS D, FRÖHLICH-REITERER E, CRAIG M. 1580-P: Hemoglobin A1c (HbA1c) Trajectories of Youth with Type 1 Diabetes (T1D) over 10 Years Postdiagnosis from Three Continents. Diabetes 2020, 69 DOI: 10.2337/db20-1580-p.Peer-Reviewed Original ResearchT1D ExchangeInternational registryStable HbA1cGerman Diabetes AssociationProspective Follow-upOnset of T1D.Type 1 diabetesStudy of DiabetesAdvisory PanelEli LillyHbA1c trajectoriesT1D onsetDiabetes AssociationYears postdiagnosisAustralasian Diabetes Data NetworkDiabetes careFollow-upHarry B. Helmsley Charitable TrustGerman centersRegistryHbA1cOlder ageGreater riskDiabetes researchLexicon Pharmaceuticals